NHS England Announces Interim Policy on EAP for SMA Type 1
04 August 2017
NHS England has considered the evidence available within the European Appraisal and have today published an interim policy providing all hospital costs for administering nusinersen to patients with SMA Type 1. This is to support the access scheme offered by Biogen and will continue until either the company cease the access scheme to new patients or when the appraisal of the drug has been completed by NICE.
Biogen has committed to ensuring that all patients starting treatment, who do not reach the stopping criteria, will continue to access treatment beyond the closure of the scheme and NHS England will fund the associated treatment costs.